Elan announces exploration of EDT separation and board changes (ELN) 7.72 : Co has decided to explore the possibility of a separation of its Elan Drug Technologies business. If executed, any transaction would create two publicly listed companies: Elan BioNeurology and EDT. The purpose of this exploration is to accurately assess the opportunity and impact on shareholder value.
Market Data 
Markets 
AI
